Abstract 13237: Placental Growth Factor as a Predictor of Long-term Outcome in Patients With Acute Decompensated Heart Failure
Background: Placental growth factor (PlGF), a member of the vascular endothelial growth factor (VEGF), contribute to atherogenesis through vascular inflammation and plaque destabilization. We reported high PlGF levels (≥14.5 pg/ml) were independent predictor of adverse events in patients with chronic kidney disease, but the significance of PlGF in acute decompensated heart failure (ADHF) patients was not clear.
Methods: We have studied consecutive 437 patients with ADHF admitted to our hospital from 2011.4 through 2014.12. Among these patients, 281 patients measured PlGF levels were studied. The primary endpoint was all-cause death.
Results: To investigate the impact of PlGF levels on prognosis of ADHF, we divided patients into 2 groups according to previous cutoff levels (14.5 pg/ml). There was no significant differences in age, left ventricular ejection fraction, and estimated glomerular filtration rate between high PlGF group (≥14.5 pg/ml, n=49) and low PlGF group (<14.5 pg/ml, n=232). Kaplan-Meier analysis revealed that the patients with high PlGF group had worse prognosis than those with low PlGF group (p=0.0092) (Figure 1). Multivariate analysis revealed that PlGF was independent predictor of all-cause death (HR 1.026 [1.005-1.045], p=0.0172) (Figure 2).
Conclusions: The high placental growth factor levels at acute phase in patients with acute decompensated heart failure predicts the long-term clinical outcome independent from various prognostic factors.
Author Disclosures: Y. Nakada: None. R. Kawakami: None. T. Ueda: None. T. Nakano: None. H. Kawata: None. H. Okura: None. Y. Saito: Research Grant; Significant; Grants-in-Aid for Scientific Research (B) Challenging Exploratory Research (FY 2015) Health, Labour and Welfare Scientific Research. Other Research Support; Modest; Nihon Medi-Physics Co.,Ltd. Chugai Pharmaceutical Co., Ltd. Genzyme Japan K.K. Medtronic, Inc. Pfizer Japan Inc.. Other Research Support; Significant; MSD K.K. a subsidiary of Merck & Co., Inc. Daiichi Sankyo Co., Ltd. Bayer Holding Ltd. Baxter Ltd. Otsuka Pharmaceutical Co., Ltd. Kyowa Hakko Kirin Co., Ltd. Dainippon Sumitomo Pharma Co., Ltd. Astel. Honoraria; Modest; Otsuka Pharmaceutical Co., Ltd Takeda Pharmaceutical Co., Ltd Mitsubishi Tanabe Pharma Corporation Daiichi Sankyo Co., Ltd MSD K.K. a subsidiary of Merck & Co., Inc Novartis Pharma K.K. Bayer Holding. Consultant/Advisory Board; Modest; Novartis Pharma K.K. Ono Pharmatical Co., Ltd Pfizer Japan Inc..
- © 2016 by American Heart Association, Inc.